JP5642793B2 - 糖尿病の処置に有用なｈｓｌインヒビター - Google Patents
糖尿病の処置に有用なｈｓｌインヒビター Download PDFInfo
- Publication number
- JP5642793B2 JP5642793B2 JP2012528339A JP2012528339A JP5642793B2 JP 5642793 B2 JP5642793 B2 JP 5642793B2 JP 2012528339 A JP2012528339 A JP 2012528339A JP 2012528339 A JP2012528339 A JP 2012528339A JP 5642793 B2 JP5642793 B2 JP 5642793B2
- Authority
- JP
- Japan
- Prior art keywords
- piperidine
- phenyl
- carboxylic acid
- amide
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SUJFZOLCHHPADK-UHFFFAOYSA-N CC1CC(CC(C(C)(CC=C)F)Oc2ccc(C)cc2)CC1 Chemical compound CC1CC(CC(C(C)(CC=C)F)Oc2ccc(C)cc2)CC1 SUJFZOLCHHPADK-UHFFFAOYSA-N 0.000 description 1
- HONYCPXSPSSELA-UHFFFAOYSA-N COC1=CC=C(CC(C(C(CC2)CCN2S(c2ccccc2)(=O)=[O]=C)=O)=[IH])N=CC[IH]1 Chemical compound COC1=CC=C(CC(C(C(CC2)CCN2S(c2ccccc2)(=O)=[O]=C)=O)=[IH])N=CC[IH]1 HONYCPXSPSSELA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170071.6 | 2009-09-11 | ||
| EP09170071 | 2009-09-11 | ||
| PCT/EP2010/063078 WO2011029808A1 (en) | 2009-09-11 | 2010-09-07 | Hsl inhibitors useful in the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013504533A JP2013504533A (ja) | 2013-02-07 |
| JP5642793B2 true JP5642793B2 (ja) | 2014-12-17 |
Family
ID=42983383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528339A Expired - Fee Related JP5642793B2 (ja) | 2009-09-11 | 2010-09-07 | 糖尿病の処置に有用なｈｓｌインヒビター |
Country Status (16)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686303B1 (de) | 2011-03-18 | 2016-01-20 | Bayer Intellectual Property GmbH | N-(3-carbamoylphenyl)-1h-pyrazol-5-carboxamid- derivate und ihre verwendung zur bekämpfung von tierischen schädlingen |
| JP6263789B2 (ja) | 2012-09-10 | 2018-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 |
| WO2018104220A1 (en) * | 2016-12-09 | 2018-06-14 | Boehringer Ingelheim International Gmbh | Sulfonamides as inhibitors of the uptake of extracellular citrate |
| GB2560713A (en) * | 2017-03-20 | 2018-09-26 | Eternygen Gmbh | Inhibitor of citrate transporter |
| CN110003177B (zh) * | 2019-05-28 | 2021-11-19 | 沈阳药科大学 | 含有脲基的苯并咪唑类化合物及应用 |
| CN110003176B (zh) * | 2019-05-28 | 2021-12-21 | 沈阳药科大学 | 含有酰胺的苯并咪唑类化合物及其应用 |
| GB201918410D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
| WO2022130352A1 (en) * | 2020-12-19 | 2022-06-23 | Cadila Healthcare Limited | Novel compounds suitable for the treatment of dyslipidemia |
| GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3779339B2 (ja) | 1994-03-04 | 2006-05-24 | 三井化学株式会社 | 含フッ素カルボン酸エステル化合物、液晶材料、液晶組成物および液晶素子 |
| WO1999065867A1 (en) * | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| MXPA04004674A (es) | 2001-11-14 | 2004-08-12 | Schering Corp | Ligados de los receptors de los canabinodies. |
| KR100979577B1 (ko) * | 2005-03-03 | 2010-09-01 | 에프. 호프만-라 로슈 아게 | 2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체 |
| TW200806675A (en) * | 2006-01-30 | 2008-02-01 | Array Biopharma Inc | Heterobicyclic thiophene compounds and methods of use |
| EP2038255A2 (en) * | 2006-06-16 | 2009-03-25 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted piperidine carboxamides |
| EP1958631A1 (en) | 2007-02-14 | 2008-08-20 | AEterna Zentaris GmbH | Novel triazole derivatives as ligands of G-protein coupled receptors |
| US8324250B2 (en) | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8399676B2 (en) * | 2009-07-30 | 2013-03-19 | Hoffman-La Roche Inc. | Piperidine derivatives |
-
2010
- 2010-09-03 US US12/875,446 patent/US8258158B2/en not_active Expired - Fee Related
- 2010-09-07 ES ES10751931.6T patent/ES2445166T3/es active Active
- 2010-09-07 CN CN201080039803.8A patent/CN102498099B/zh not_active Expired - Fee Related
- 2010-09-07 EP EP10751931.6A patent/EP2475644B1/en not_active Not-in-force
- 2010-09-07 IN IN1232DEN2012 patent/IN2012DN01232A/en unknown
- 2010-09-07 AU AU2010294326A patent/AU2010294326A1/en not_active Abandoned
- 2010-09-07 JP JP2012528339A patent/JP5642793B2/ja not_active Expired - Fee Related
- 2010-09-07 WO PCT/EP2010/063078 patent/WO2011029808A1/en not_active Ceased
- 2010-09-07 CA CA2771452A patent/CA2771452A1/en not_active Abandoned
- 2010-09-07 KR KR1020127009254A patent/KR101369551B1/ko not_active Expired - Fee Related
- 2010-09-07 BR BR112012005140A patent/BR112012005140A2/pt not_active Application Discontinuation
- 2010-09-07 MX MX2012002597A patent/MX2012002597A/es active IP Right Grant
- 2010-09-07 SG SG2012016085A patent/SG179031A1/en unknown
- 2010-09-08 TW TW099130350A patent/TW201114744A/zh unknown
- 2010-09-09 AR ARP100103302A patent/AR078351A1/es unknown
-
2012
- 2012-02-06 IL IL217966A patent/IL217966A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102498099B (zh) | 2014-10-29 |
| JP2013504533A (ja) | 2013-02-07 |
| WO2011029808A1 (en) | 2011-03-17 |
| CA2771452A1 (en) | 2011-03-17 |
| SG179031A1 (en) | 2012-04-27 |
| IN2012DN01232A (cg-RX-API-DMAC10.html) | 2015-05-15 |
| AR078351A1 (es) | 2011-11-02 |
| US8258158B2 (en) | 2012-09-04 |
| ES2445166T3 (es) | 2014-02-28 |
| KR101369551B1 (ko) | 2014-03-04 |
| KR20120059617A (ko) | 2012-06-08 |
| HK1169993A1 (en) | 2013-02-15 |
| IL217966A0 (en) | 2012-03-29 |
| EP2475644B1 (en) | 2014-01-08 |
| MX2012002597A (es) | 2012-04-02 |
| BR112012005140A2 (pt) | 2016-05-03 |
| EP2475644A1 (en) | 2012-07-18 |
| AU2010294326A1 (en) | 2012-03-08 |
| CN102498099A (zh) | 2012-06-13 |
| TW201114744A (en) | 2011-05-01 |
| US20110065707A1 (en) | 2011-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5642793B2 (ja) | 糖尿病の処置に有用なｈｓｌインヒビター | |
| JP5542916B2 (ja) | Ｈｓｌ阻害薬としてのアザ環式スピロ誘導体 | |
| JP5956423B2 (ja) | Ｈｓｌ阻害剤としてのアザ環式スピロ誘導体 | |
| US9365539B2 (en) | Prolylcarboxypeptidase inhibitors | |
| US8440710B2 (en) | HSL inhibitors useful in the treatment of diabetes | |
| CN102639533B (zh) | 氮杂环螺衍生物 | |
| CN103415506B (zh) | 作为用于治疗糖尿病的hsl抑制剂的仲-羟基环己基衍生物 | |
| CN103429569B (zh) | 氮杂螺环癸酮化合物 | |
| CN103429587B (zh) | 作为hsl抑制剂的氮杂螺环癸酮化合物 | |
| JP5503000B2 (ja) | ピペリジン誘導体並びに肥満症、糖尿病、脂質異常症及びアテローム動脈硬化症を処置するためのその使用 | |
| JP5886282B2 (ja) | 新規なアザ環状化合物 | |
| HK1169993B (en) | Hsl inhibitors useful in the treatment of diabetes | |
| HK1191326B (en) | Azaspirodecanone compounds | |
| HK1168597A (en) | Azacyclic spiro derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140314 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140930 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5642793 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |